Health Economics›Cutaneous T-cell lymphoma›Relapsed or refractory

Relapsed or refractory

Cutaneous T-cell lymphoma · 14 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Alemtuzumab monotherapy Variant #03	—	R 267 680	7d	~15.0 mo	—	~1	~R 267 680 PFS proxy · indirect	—
Brentuximab vedotin monotherapy Variant #01	—	R 56 829	21d	~16.7 mo	—	~17	~R 966 097 PFS proxy · indirect	1
Bendamustine monotherapy Variant #01	—	R 7 084	—	~16.5 mo	—	~8	~R 56 672 PFS proxy · indirect	2
Lenalidomide monotherapy Variant #01	—	R 2 178	28d	~39.0 mo	~113.8 mo	~13	~R 28 314 PFS proxy · indirect	10
Denileukin diftitox monotherapy Variant #01 Partial	—	—	21d	—	—	~8	—	—
Pralatrexate monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	1
Placebo Partial	—	—	—	~4.2 mo	~8.0 mo	—	—	145
Belinostat monotherapy Variant #01 Partial	—	—	21d	—	—	~2	—	—
Methotrexate monotherapy Partial	—	—	—	~3.5 mo	—	—	—	1
Bexarotene monotherapy Variant #01 Partial	—	—	336d	~3.5 mo	—	~2	—	1
Bexarotene and Pralatrexate Variant #01 Partial	—	—	28d	—	—	~2	—	—
Mogamulizumab monotherapy Variant #01 Partial	—	—	7d	~7.7 mo	—	~8	—	1
Romidepsin monotherapy Variant #01 Partial	—	—	28d	—	—	~6	—	1
Vorinostat monotherapy Variant #01 Partial	—	—	28d	~3.1 mo	—	~12	—	1

14 of 14 regimens shown